Sinus Implant Launches During Start of Strong Allergy Season

Intersect ENT is launching its Sinuva Sinus Implant, a new approach to treating nasal polyp disease in adult patients who have had previous sinus surgery.  The Menlo Park, CA-based company said nearly 635,000 Americans have gone through these surgeries and are looking for treatments to cure side effects. Sinuva’s targeted launch comes at an opportune time – right in the middle of allergy season. “We were really looking at the launch regardless of the time of year,” Susan Stinson, general manager at Intersect ENT, told MD+DI. “The timing however, we believe works out very much in our favor in that in the first quarter we had the opportunity to train our salesforce at our national sales meeting. It just so happens that the timing of the launch coincides with allergy season and tends to drive many patients who have an exacerbation of their symptoms into their ENT physician’s office.” Join us at the BIOMEDevice Boston Expo,  April 18–19, 2018. Use promo code "MDDI" for 20% off conference registration and free expo access.   Sinuva is placed during a routine office visit and it is designed to provide a less invasive treatment option for patients who have previously undergone sinus surgery, yet suffer from recurrent sinus obstruction. The company said the device delivers anti-inflammatory medication directly to the site of the disease. The technology differs from Intersect ENT’s Propel Implant. The Propel Contour  features a low-profile flexible delivery sys...
Source: MDDI - Category: Medical Devices Authors: Tags: Implants Business Source Type: news